Praxis Precision Medicines Inc (NASDAQ:PRAX) has a beta value of 2.70 and has seen 1.1 million shares traded in the last trading session. The company, currently valued at $1.36B, closed the last trade at $73.01 per share which meant it gained $0.63 on the day or 0.87% during that session. The PRAX stock price is -19.07% off its 52-week high price of $86.93 and 78.82% above the 52-week low of $15.46. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.32 million shares traded. The 3-month trading volume is 310.70K shares.

The consensus among analysts is that Praxis Precision Medicines Inc (PRAX) is Buy stock at the moment, with a recommendation rating of 1.30. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 5 have rated it as a Hold, with 4 advising it as a Buy. 0 have rated the stock as Underweight.

Praxis Precision Medicines Inc (NASDAQ:PRAX) trade information

Sporting 0.87% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the PRAX stock price touched $73.01 or saw a rise of 3.92%. Year-to-date, Praxis Precision Medicines Inc shares have moved 227.69%, while the 5-day performance has seen it change 4.45%. Over the past 30 days, the shares of Praxis Precision Medicines Inc (NASDAQ:PRAX) have changed 1.74%. Short interest in the company has seen 1.47 million shares shorted with days to cover at 3.97.

Wall Street analysts have a consensus price target for the stock at $75.38, which means that the shares’ value could jump 3.14% from current levels. The projected low price target is $60.3 while the price target rests at a high of $85.43. In that case, then, we find that the current price level is -17.01% off the targeted high while a plunge would see the stock lose 17.41% from current levels.

Praxis Precision Medicines Inc (PRAX) estimates and forecasts

Figures show that Praxis Precision Medicines Inc shares have outperformed across the wider relevant industry. The company’s shares have gained 93.71% over the past 6 months, with this year growth rate of 45.10%, compared to 17.20% for the industry.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -10.28% over the past 5 years. Earnings growth for 2024 is a modest 45.43% while over the next 5 years, the company’s earnings are expected to decrease by -14.60%.

PRAX Dividends

Praxis Precision Medicines Inc is expected to release its next earnings report in January this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.

Praxis Precision Medicines Inc (NASDAQ:PRAX)’s Major holders

Insiders own 0.24% of the company shares, while shares held by institutions stand at 104.01% with a share float percentage of 104.27%. Investors are also buoyed by the number of investors in a company, with Praxis Precision Medicines Inc having a total of 189.0 institutions that hold shares in the company. The top two institutional holders are RA CAPITAL MANAGEMENT, L.P. with over 1.24 million shares worth more than $51.1 million. As of 2024-06-30, RA CAPITAL MANAGEMENT, L.P. held 6.5638% of shares outstanding.

The other major institutional holder is ADAGE CAPITAL PARTNERS GP, L.L.C., with the holding of over 1.13 million shares as of 2024-06-30. The firm’s total holdings are worth over $46.91 million and represent 6.0245% of shares outstanding.

Also the top two Mutual Funds that are holding company’s shares are Smallcap World Fund and Vanguard Total Stock Market Index Fund . As of Sep 30, 2024 , the former fund manager holds about 4.76% shares in the company for having 888.06 shares of worth $64.84 million while later fund manager owns 541.27 shares of worth $39.52 million as of Sep 30, 2024 , which makes it owner of about 2.90% of company’s outstanding stock.